On May 29, 2024, Michelle Basil, Executive Vice President and General Counsel of Haemonetics Corp (HAE, Financial), executed a sale of 12,990 shares of the company at a price of $88.08 per share. This transaction was documented in the SEC Filing. Following this sale, the insider now owns 31,257 shares of Haemonetics Corp.
Haemonetics Corp is a healthcare company that specializes in blood and plasma supplies and services. The company's products and solutions are used in blood collection, separation, and processing endeavors, serving a critical role in medical treatments and procedures.
Over the past year, Michelle Basil has sold a total of 16,652 shares and has not purchased any shares. This recent transaction is part of a broader trend observed within Haemonetics Corp, where there have been 15 insider sells and no insider buys over the past year.
Shares of Haemonetics Corp were trading at $88.08 on the day of the transaction, giving the company a market cap of approximately $4.45 billion. The price-earnings ratio of the company stands at 38.20, which is above the industry median of 28.97.
The stock is currently assessed as Fairly Valued with a GF Value of $92.69, leading to a price-to-GF-Value ratio of 0.95. The GF Value is calculated considering historical trading multiples, an adjustment factor based on past returns and growth, and future business performance estimates.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
